Neurocrine Biosciences (NASDAQ:NBIX) Insider Jude Onyia Sells 11,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $155.53, for a total transaction of $1,710,830.00. Following the completion of the transaction, the insider directly owned 25,846 shares of the company’s stock, valued at approximately $4,019,828.38. This represents a 29.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $158.30 on Friday. The company has a market cap of $15.92 billion, a PE ratio of 24.39, a P/E/G ratio of 1.17 and a beta of 0.34. The company has a fifty day moving average price of $139.36 and a two-hundred day moving average price of $139.16. Neurocrine Biosciences, Inc. has a 12 month low of $121.42 and a 12 month high of $162.39.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $25,000. Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. DJE Kapital AG bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $28,000. Finally, Cassaday & Co Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences during the first quarter valued at about $33,000. 92.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright lifted their price objective on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Needham & Company LLC reissued a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a report on Monday, April 6th. Wells Fargo & Company reduced their price target on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Wolfe Research started coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They set an “outperform” rating and a $160.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $186.05.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.